Last reviewed · How we verify
[68Ga]Ga-PentixaFor
Ga-PentixaFor is a radiopharmaceutical that targets the CD47/SIRPα axis.
Ga-PentixaFor is a radiopharmaceutical that targets the CD47/SIRPα axis. Used for Assessment of myocardial infarction and acute coronary syndrome.
At a glance
| Generic name | [68Ga]Ga-PentixaFor |
|---|---|
| Also known as | CXCR4, [68Ga]Ga-PTF |
| Sponsor | Nantes University Hospital |
| Drug class | Radiopharmaceutical |
| Target | CD47 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Ga-PentixaFor binds to the CD47 protein on the surface of cancer cells, which can be recognized by the SIRPα receptor on the surface of macrophages. This interaction can inhibit the immune suppressive effects of CD47 and promote the phagocytosis of cancer cells by macrophages.
Approved indications
- Assessment of myocardial infarction and acute coronary syndrome
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Fatigue
- Headache